利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.02 秒)

    Production of streptavidin-like polypeptides
    1.
    发明授权
    Production of streptavidin-like polypeptides 失效
    链霉亲和素样多肽的制备

    公开(公告)号：US5272254A

    公开(公告)日：1993-12-21

    申请号：US800158

    申请日：1991-11-27

    申请人： Harry M. Meade ,  Jeffrey L. Garwin

    发明人： Harry M. Meade ,  Jeffrey L. Garwin

    IPC分类号： C07K14/36 ,  C12N9/72 ,  C12N15/76 ,  C07K13/00 ,  C07K7/00

    CPC分类号： C12N9/6459 ,  C07K14/36 ,  C12N15/76 ,  C12Y304/21069 ,  C07K2319/02 ,  C07K2319/22 ,  C07K2319/33 ,  Y10S530/825

    摘要： DNA sequences, hybrid DNA sequences, recombinant DNA molecules and processes for producing streptavidin-like polypeptides and for producing fused proteins consisting of a streptavidin-like polypeptide joined end to end with another protein, polypeptide, peptide or amino acid. The DNA sequences, hybrid DNA sequences and recombinant DNA molecules of this invention are characterized in that they include DNA fragments that code for streptavidin-like polypeptides. These DNA sequences, hybrid DNA sequences and recombinant DNA molecules and the hosts transformed with them may be employed in the processes of this invention to produce streptavidin-like polypeptides and fused proteins.

    摘要翻译： DNA序列，杂交DNA序列，重组DNA分子和用于产生链霉抗生物素蛋白样多肽和用于产生由链霉抗生物素蛋白样多肽组成的融合蛋白的方法与另一种蛋白质，多肽，肽或氨基酸端到端连接。 本发明的DNA序列，杂交DNA序列和重组DNA分子的特征在于它们包括编码链霉抗生物素蛋白样多肽的DNA片段。 这些DNA序列，杂交DNA序列和重组DNA分子以及用它们转化的宿主可用于本发明的方法中以产生链霉抗生物素蛋白样多肽和融合蛋白。

    METHOD FOR PROGNOSING RESPONSE TO CANCER THERAPY WITH 5, 10, 15, 20-TETRAKIS (CARBOXYPHENYL) PORPHINE
    3.
    发明申请
    METHOD FOR PROGNOSING RESPONSE TO CANCER THERAPY WITH 5, 10, 15, 20-TETRAKIS (CARBOXYPHENYL) PORPHINE 有权
    用5,10,15,20-TETRAKIS（羧甲基）磷酸酯预防癌症治疗反应的方法

    公开(公告)号：US20120149057A1

    公开(公告)日：2012-06-14

    申请号：US13158595

    申请日：2011-06-13

    申请人： Jeffrey L. Garwin

    发明人： Jeffrey L. Garwin

    IPC分类号： G01N21/64

    CPC分类号： G01N33/574 ,  A61K31/409 ,  G01N33/5091 ,  G01N33/52

    摘要： Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

    摘要翻译： 提出了一种预测患者对癌症治疗的反应的方法，其中在治疗之前接触来自患者的组织或被治疗癌症的器官的细胞样品与TCPP的溶液接触以允许TCPP与异常组分的结合 发育不良或癌细胞（如有）; 检测样品中的TCPP荧光，TCPP荧光的存在表明样品含有发育异常或癌细胞; 在治疗期间以及在治疗后对来自患者被治疗癌症的组织或器官的另一个细胞样品进行a-c的治疗后， 并且确定在治疗期间和之后测试的样品中异常的前癌细胞的百分比是否与在治疗之前测试的样品相比减少，所述减少是患者对癌症治疗的反应的预后。

    Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine
    4.
    发明授权
    Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine 有权
    用5,10,15,20-四（羧基苯基）卟吩预防癌症治疗反应的方法

    公开(公告)号：US08486656B2

    公开(公告)日：2013-07-16

    申请号：US13158595

    申请日：2011-06-13

    申请人： Jeffrey L. Garwin

    发明人： Jeffrey L. Garwin

    IPC分类号： G01N1/30

    CPC分类号： G01N33/574 ,  A61K31/409 ,  G01N33/5091 ,  G01N33/52

    摘要： Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

    摘要翻译： 提出了一种预测患者对癌症治疗的反应的方法，其中在治疗之前接触来自患者的组织或被治疗癌症的器官的细胞样品与TCPP的溶液接触以允许TCPP与异常组分的结合 发育不良或癌细胞（如有）; 检测样品中的TCPP荧光，TCPP荧光的存在表明样品含有发育异常或癌细胞; 在治疗期间以及在治疗后对来自患者被治疗癌症的组织或器官的另一个细胞样品进行a-c的治疗后， 并且确定在治疗期间和之后测试的样品中异常的前癌细胞的百分比是否与在治疗之前测试的样品相比减少，所述减少是患者对癌症治疗的反应的预后。

    Eggs compatible with cholesterol-reducing diet and method of producing the same
    6.
    发明授权
    Eggs compatible with cholesterol-reducing diet and method of producing the same 失效
    与降胆固醇饮食兼容的鸡蛋和生产相同的方法

    公开(公告)号：US5246717A

    公开(公告)日：1993-09-21

    申请号：US785976

    申请日：1991-10-31

    申请人： Jeffrey L. Garwin

    发明人： Jeffrey L. Garwin

    IPC分类号： A23K1/16 ,  A23K1/175 ,  A23K1/18 ,  A23L1/32

    CPC分类号： A23K50/75 ,  A23K20/00 ,  A23K20/158 ,  A23K20/174 ,  A23K20/30 ,  A23L15/00 ,  Y10S426/805

    摘要： Chicken eggs are provided which contain controlled amounts of vitamin E and iodine. No more than about 34% of the fatty acid content of the eggs comprises saturated fatty acid. The eggs may be eaten in the context of a standard low fat diet, without increasing the dieter's serum cholesterol concentration. The eggs are produced by maintaining egg laying chickens on a diet free of animal fat, wherein conventional feed is supplemented with controlled amounts of unsaturated fatty acid, iodine and vitamin E.

    摘要翻译： 提供含有受控量维生素E和碘的鸡蛋。 不超过约34％的蛋的脂肪酸含量包括饱和脂肪酸。 可以在标准低脂肪饮食的背景下吃蛋，而不增加食量的血清胆固醇浓度。 鸡蛋是通过在没有动物脂肪的饮食上维持产卵鸡来制备的，其中常规饲料中补加有受控量的不饱和脂肪酸，碘和维生素E.

    Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine
    10.
    发明授权
    Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine 有权
    用5,10,15,20-四（羧基苯基）卟吩预防癌症治疗反应的方法

    公开(公告)号：US07960138B2

    公开(公告)日：2011-06-14

    申请号：US12715627

    申请日：2010-03-02

    申请人： Jeffrey L. Garwin

    发明人： Jeffrey L. Garwin

    IPC分类号： G01N1/30

    CPC分类号： G01N33/574 ,  A61K31/409 ,  G01N33/5091 ,  G01N33/52

    摘要： Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

    摘要翻译： 提出了一种预测患者对癌症治疗的反应的方法，其中在治疗之前接触来自患者的组织或被治疗癌症的器官的细胞样品与TCPP的溶液接触以允许TCPP与异常组分的结合 发育不良或癌细胞（如有）; 检测样品中的TCPP荧光，TCPP荧光的存在表明样品含有发育异常或癌细胞; 在治疗期间以及在治疗后对来自患者被治疗癌症的组织或器官的另一个细胞样品进行a-c的治疗后， 并且确定在治疗期间和之后测试的样品中异常的前癌细胞的百分比是否与在治疗之前测试的样品相比减少，所述减少是患者对癌症治疗的反应的预后。